GC Genome

What GC Genome does

GC Genome is a South Korea-based clinical genomics diagnostic company founded in August 2013 as a spin-off from the GC (Green Cross) conglomerate. The company provides B2B genetic testing services to over 900 hospitals and clinics across five verticals: cancer diagnostics (hereditary cancer panels, solid tumor profiling across 523 genes, hematologic malignancies, GreenPlan HRD as Korea's first domestically approved HRD test, and distributed Guardant360/Guardant Reveal liquid biopsy), rare disease diagnostics (CMA, TES, WES, DGS, GC-REP long-read repeat expansion), health checkup testing (including the flagship ai-CANCERCH multi-cancer screening), prenatal/neonatal screening (G-NIPT with 99.79% Down syndrome sensitivity, Prenatal CMA, i-screen, M-screen), and organ transplant monitoring (dd-cfDNA).

The core technology platform combines next-generation sequencing (NGS), whole genome sequencing (WGS), and the proprietary FEMS (Fragment End Motif frequency by Size) AI algorithm, which jointly analyzes cfDNA fragment size and end-motif sequence patterns to detect cancer signals at low concentrations. This is supported by a proprietary Korean-population variant database (GC-MD), custom variant interpretation algorithms (GC-VIP, GC-CNema, GC-CSI, GC-CMA), and an 8,500-sample clinical validation cohort. Reported ai-CANCERCH performance includes 95.5% specificity, 79.7% sensitivity, 80.2% stage-weighted sensitivity, 90.4% sensitivity/94.7% specificity for colorectal cancer detection, and up to 87% sensitivity for early-stage pancreatic cancer.

Revenue is generated through laboratory testing services billed to medical institutions on a per-test basis, with the company operating a sales-led GTM targeting hospitals, clinics, and academic medical centers. GC Genome listed on KOSDAQ in June 2025 (ticker 340450, technology-specialty listing) with a 547.5:1 demand forecasting competition ratio. The company holds CAP, MFDS GCLP, and Korean Genetic Testing Evaluation Center A-grade certifications, and is expanding internationally through subsidiary GC Lymphotec in Japan (ai-CANCERCH launched April 2025), partnerships with Advanced Cell Laboratory and Genalive in Saudi Arabia, and bio LAB in Bahrain.

Name

GC Genome

Legal name

주식회사 지씨지놈

Website

https://gcgenome.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

GC Genome is a South Korea-based clinical genomics company providing B2B genetic testing to 900+ hospitals across cancer, rare disease, prenatal, and health checkup verticals, with proprietary AI-driven multi-cancer screening technology and KOSDAQ listing since June 2025.

Ownership category

akta.pro rank

Product category

Clinical Genomic Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Clinical genetic testing
• Liquid biopsy diagnostics
• Cancer genomic profiling
• Non-invasive prenatal testing
• Rare disease diagnostics

Headquarters

HQ city

Giheung

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Genetic Testing Services: GC Genome provides a wide range of genetic testing services to hospitals and clinics, including cancer testing, prenatal screening, rare disease diagnostics, and health checkup tests. Revenue is generated through laboratory testing services billed to medical institutions.
2. Diagnostic Testing (KOSDAQ Listed Company): As a publicly listed company on KOSDAQ (June 2025), GC Genome generates revenue through its clinical genetic testing laboratory services, providing tests to over 900 hospitals and clinics domestically.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

GC Genome is a clinical genomics diagnostic laboratory that sells NGS-based and AI-driven genetic testing services to hospitals and clinics across five categories: cancer diagnostics (hereditary, solid tumor, hematologic, HRD), rare disease testing (CMA, TES, WES, DGS, GC-REP), health checkup screening (ai-CANCERCH multi-cancer, Genome Health, GreenBiome, Telorisk, pharmacogenetics), prenatal/neonatal screening (G-NIPT, Prenatal CMA, i-screen, M-screen), and transplant monitoring (dd-cfDNA). Tests are ordered by physicians, samples are processed in GC Genome's central laboratory, and results are returned to medical institutions, with over 900 hospitals and clinics served domestically.

Product overview

GC Genome is a clinical genomics diagnostic company offering a comprehensive portfolio of genetic testing services organized into five main categories: Cancer Testing (hereditary, solid tumor, hematologic, HRD, and Guardant Health distributed products), Rare Disease Testing (CMA, TES, WES, DGS, GC-REP), Health Checkup Testing (ai-CANCERCH multi-cancer screening, Genome Health, GreenBiome microbiome, Genome Screen, Telorisk, Pharmacogenetics), Prenatal/Neonatal Testing (G-NIPT, Prenatal CMA, i-screen, M-screen), and Organ Transplant Testing (dd-cfDNA). The company's flagship product is ai-CANCERCH, an AI-powered multi-cancer early detection blood test launched in 2023. GC Genome operates primarily as a B2B service provider to hospitals and clinics, offering 300+ genetic testing services to 900+ medical institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• ai-CANCERCH (아이캔서치) AI-based multi-cancer early detection blood test that screens for 10 cancer types (stomach, liver, lung, colon, pancreas, bile duct, esophagus, head/neck, breast, ovarian) from a single blood draw using cfDNA analysis and proprietary FEMS AI algorithm. Targeted at health checkup patients and cancer screening programs through hospitals and clinics.
• GreenPlan Hereditary Cancer (그린플랜 유전성 암) NGS-based hereditary cancer genetic test examining dozens of hereditary cancer types including BRCA1/2, MLH1/MSH2 for identifying pathogenic variants in cancer predisposition genes. Used by oncology departments and cancer genetics clinics for patients with suspected hereditary cancer syndromes.
• GreenPlan Solid Tumor (그린플랜 고형암) NGS-based test using tissue and liquid biopsy to detect somatic mutations across 523 genes for genetic diagnosis, treatment decisions, and prognosis in solid tumor cancers. Used by oncologists for solid tumor patients requiring targeted therapy guidance.
• GreenPlan Hematology (그린플랜 혈액암) NGS-based genetic test for diagnosis, treatment, and prognosis of hematologic malignancies including leukemia, myelodysplastic/myeloproliferative neoplasms, malignant lymphoma, and multiple myeloma. Used by hematology departments for blood cancer patients.
• GreenPlan HRD (그린플랜 HRD) First domestically approved HRD (Homologous Recombination Deficiency) test in Korea. Identifies ovarian cancer patients eligible for PARP inhibitor therapy by examining BRCA1/2 somatic mutations, HRR gene mutations, and genomic instability scores (LOH, TAI, LST). Identifies up to 50% of ovarian cancer patients as PARP inhibitor candidates versus 20-30% with BRCA-only testing.
• Guardant360 FDA-approved liquid biopsy test from Guardant Health distributed in Korea by GC Genome. Profiles circulating tumor DNA to detect 70+ clinically relevant genetic variants for targeted and immunotherapy treatment decisions in advanced solid tumor cancers.
• Guardant Reveal Liquid biopsy minimal residual disease (MRD) test for detecting circulating tumor DNA in post-surgical stage 2/3 colorectal, breast, and lung cancer patients to predict recurrence and monitor treatment response. Distributed in Korea by GC Genome under partnership with Guardant Health.
• CMA (Chromosomal Microarray) Chromosomal microarray test detecting copy number variations (CNV), loss of heterozygosity (LOH), and uniparental disomy (UPD) for diagnosing chromosomal disorders. Used in rare disease diagnostics for pediatric and adult patients with suspected chromosomal abnormalities.
• TES (Targeted Exome Sequencing) Targeted exome sequencing test examining dozens to hundreds of genes simultaneously for diagnosing diseases with similar symptoms, detecting SNV, indel, and CNV variants. Used for undiagnosed rare disease patients with suspected genetic etiology.
• WES (Whole Exome Sequencing) Whole exome sequencing test covering approximately 20,000+ human genes including exons and mitochondrial DNA for comprehensive genetic analysis. Used for undiagnosed rare disease cases (research use only).
• DGS (Diagnostics Genome Sequencing) Diagnostic whole genome sequencing test examining approximately 20,000+ genes including exons and introns, covering approximately 3 billion base pairs for comprehensive genomic analysis in rare disease cases.
• GC-REP (Long-Read Repeat Expansion Panel) PacBio HiFi long-read sequencing-based targeted analysis test for diagnosing repeat expansion disorders that are difficult to detect with existing tests, covering 38 targeted genes.
• G-NIPT (지니프트) Non-invasive prenatal screening test analyzing cell-free fetal DNA from maternal blood to screen for chromosomal abnormalities including Down, Edwards, and Patau syndromes with 99.79% sensitivity and less than 0.1% false positive rate. Used by obstetricians for pregnant women seeking safe prenatal screening.
• M-screen Miscarriage genetic analysis test examining chromosomal numerical and structural abnormalities (deletion/duplication) from conceptus tissue to identify genetic causes of pregnancy loss. Used by obstetricians and reproductive medicine clinics.
• i-screen (아이스크린) Newborn genetic screening test examining chromosomal abnormalities associated with intellectual disability, developmental disorders, autism, and growth delays through chromosomal analysis. Used by pediatric departments for newborn and infant screening.
• Genome Health (지놈헬스) Total lifecycle care genetic test examining disease-susceptibility genetic factors and lifestyle-related genetic factors for personalized health management guidance across dozens of conditions. Used by health checkup centers for preventive screening.
• GreenBiome (그린바이옴) Intestinal and vaginal microbiome analysis service examining gut bacteria and vaginal microbiome genetics to provide microbiome health information. Includes GreenBiome Gut for gut health and GreenBiome Lady for women's vaginal microbiome health (launched January 2023).
• Genome Screen (지놈 스크린) Genetic test examining pathogenic variants across disease-related genes, including cancer (24 types), cardiac sudden death (15 types), hypercholesterolemia (12 types), and stroke (23 types). Used by health screening centers for comprehensive genetic risk assessment.
• Telorisk (텔로리스크) Telomere length test providing predicted telomere length, predicted biological age, and aging speed to assess biological aging status for preventive health management.
• Pharmacogenetics DNA (약물적합도 DNA) Pharmacogenetics test examining 10 genetic factors related to adverse drug reactions and drug efficacy reduction across 38 medications for hypertension, kidney disease, diabetes, hyperlipidemia, digestive disorders, and inflammatory conditions.
• dd-cfDNA (Donor-Derived Cell-Free DNA) Donor-derived cell-free DNA test for monitoring acute rejection in kidney, heart, lung, and liver transplant recipients by measuring dd-cfDNA levels in blood. Used by transplant centers for non-invasive rejection surveillance.
• Prenatal CMA (산전 CMA) Chromosomal microarray test for prenatal diagnosis of fetal chromosomal numerical and structural abnormalities with higher diagnostic value than conventional karyotyping. Used by obstetricians for high-risk pregnancies.
• JinSkech (진스케치) Personalized health management genetic factor test for analyzing disease vulnerability genetic factors. Used by health checkup centers for individualized health risk profiling.

Quantifiable outcome

• 99.79% sensitivity for Down syndrome detection with <0.1% false positive rate for G-NIPT
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Partnerships

Eleven partnerships are on record, tiered core and major.

• Genece Health (USA)coreTechnology or Integration · 1 January 2023Licensed liquid biopsy core technology from US-based Genece Health in 2023, enabling GC Genome to strengthen its liquid biopsy capabilities for cancer detection.
• Asan Medical CentercoreStrategic or Co-development PartnerStrategic partnership with Asan Medical Center as part of the Korean Medical Center (KMC) initiative in Qatar. Asan is one of Korea's leading medical institutions, providing expertise and credibility to GC Genome's international healthcare gateway positioning.
• EHL Biotechnology InstitutecoreStrategic or Co-development PartnerStrategic partnership with EHL Biotechnology Institute as part of the Korean Medical Center initiative, contributing to GC Genome's presence in the GCC healthcare market.
• Guardant HealthcoreTechnology or IntegrationPartnership for Guardant360 and Guardant Reveal liquid biopsy tests. GC Genome serves as the Korean distributor and laboratory for Guardant Health's FDA-approved comprehensive genomic profiling and MRD tests.
• GC LymphoteccoreChannel Partner/ Reseller/ DistributorJapanese subsidiary handling ai-CANCERCH distribution and hospital network expansion in Japan following April 2025 product launch. Accelerating clinical collaboration and screening introduction discussions with Japanese medical institutions.
• Advanced Cell Laboratory (Saudi Arabia)majorChannel Partner/ Reseller/ DistributorCAP-certified molecular diagnostics laboratory in Saudi Arabia. Partnership established for technology transfer and local implementation of GC Genome's advanced analysis technologies including ai-CANCERCH testing.
• Genalive (Saudi Arabia)majorStrategic or Co-development PartnerPartners with Saudi Arabia's largest genome and data center, operating national projects. Strategic partnership established for Saudi government genome initiative participation and genetic testing collaboration.
• bio LAB (Bahrain)majorChannel Partner/ Reseller/ DistributorBahrain-based laboratory partnership for ai-CANCERCH distribution. Bahraini government hospital officials expressed high interest, proposing GC Genome's official presentation at 2025 Manama Health Congress & Expo.
• Korea University Gusang Hospital (권민정 professor team)coreStrategic or Co-development PartnerAcademic collaboration for cfDNA fragmentomics confounder analysis research. Published findings in Clinical Chemistry journal identifying liver enzymes and age as confounders in liquid biopsy cancer detection.
• Seoul National University Bundang Hospital (변정식 professor team)coreStrategic or Co-development PartnerJoint research collaboration for blood-based colorectal cancer screening technology. Study published in American Journal of Gastroenterology demonstrating high sensitivity and specificity of ai-CANCERCH for colorectal cancer detection.
• National Cancer Center Korea (공선영 professor)coreStrategic or Co-development PartnerCollaboration with National Cancer Center Korea diagnostic radiology department for pancreatic cancer early prediction study using ai-CANCERCH FEMS technology. Achieved up to 87% sensitivity for early-stage pancreatic cancer.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Guardant Health: US-based liquid biopsy leader in oncology; both a direct competitor in ctDNA-based cancer detection and a partner via Guardant360/Guardant Reveal distribution in Korea. Closest functional analog to GC Genome's oncology liquid biopsy franchise.
• Natera: US genetic testing company operating across NIPT, oncology (Signatera MRD), and organ transplant (Prospera dd-cfDNA). Directly comparable to GC Genome's G-NIPT, dd-cfDNA, and oncology MRD offerings.
• Macrogen: Korea-based genomic services company offering NGS, clinical sequencing, and bioinformatic analysis. Closest Korean domestic peer to GC Genome in clinical sequencing services and research support.
• Seegene: Korea-headquartered molecular diagnostics company developing multiplex PCR-based assays for infectious disease, oncology, and genetic testing. Competes in the Korean clinical diagnostics market with overlapping hospital-channel reach.
• Myriad Genetics: US-based genetic testing pioneer with hereditary cancer (BRACAnalysis), prenatal, and oncology risk tests. Highly comparable in hereditary cancer, NIPT, and risk-assessment product structure.
• NeoGenomics: US oncology-focused clinical laboratory providing NGS-based solid tumor and hematologic malignancy profiling. Comparable in tumor profiling, hematology NGS, and hospital-channel sales model.
• Foundation Medicine (Roche): US leader in comprehensive genomic profiling for oncology (FoundationOne CDx/HT). Direct competitor in solid-tumor CGP that GC Genome offers through its GreenPlan Solid Tumor and Guardant360 distribution.

Broad incumbents

• Labcorp: One of the world's largest clinical laboratory networks with broad NIPT, oncology, and rare disease testing portfolios. Provides an incumbent scale benchmark against which GC Genome's specialty genomic focus competes.
• Quest Diagnostics: Large US clinical laboratory offering advanced oncology, women's health, and genetic testing services. Broad incumbent in the diagnostic testing category overlapping with multiple GC Genome segments.
• SD Biosensor: Korea-headquartered in-vitro diagnostics company with strong domestic hospital distribution. Overlaps with GC Genome in Korean diagnostic test channels and represents a regional incumbent competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gc-genome
• Facebookfacebook.com/GCGenome.Official

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GC Genome